Test RGn600 in mild to moderate Alzheimer’s patients
Part of Brain & nervous system, Mental health clinical trials.
This trial studies whether RGn600 can help people with mild to moderate Alzheimer’s disease. You may be able to join if you meet age, test-score, scan, bloodwork, and safety requirements and can attend study visits with a regular caregiver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 55 to 85 years old
- Have a doctor’s diagnosis of Alzheimer’s disease and have mild-to-moderate symptoms (MMSE score 10 to 26)
- Have blood tests and a brain CT or MRI done within the last year that match the Alzheimer’s diagnosis
- If you take Alzheimer symptom medicines or mood/behavior medicines, doses must be stable for at least 4 weeks before starting
- Have a caregiver who can reliably be with you and help during the whole study (and both you and your caregiver can sign consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This trial tests a new stem cell treatment (called RB-ADSCs) that is injected into the fluid around your brain. It aims to see if these cells can help slow down memory loss and thinking problems in people with mild to moderate Alzheimer's disease.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.